+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

From
Transdermal CNS Therapeutics to 2028 - Product Thumbnail Image

Transdermal CNS Therapeutics to 2028

  • Report
  • July 2023
  • 115 Pages
  • Global
From
From
Latin America Migraine Drugs Market 2023-2027 - Product Thumbnail Image

Latin America Migraine Drugs Market 2023-2027

  • Report
  • November 2022
  • 120 Pages
  • Latin America
From
From
From
From
From
From
CIMZIA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

CIMZIA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Lupus Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Lupus Therapeutics - Global Strategic Business Report

  • Report
  • May 2024
  • 182 Pages
  • Global
From
From
Loading Indicator